metoclopramide has been researched along with Aldosteronism in 28 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cosyntropin and metoclopramide can affect the subtyping of primary aldosteronism when used with adrenal vein sampling by exerting hormone- and side-specific effects on cortisol and aldosterone secretion." | 7.88 | Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide. ( Bisogni, V; Cesari, M; Iacobone, M; Lenzini, L; Maiolino, G; Rossi, GP; Rossitto, G; Seccia, TM, 2018) |
| "As metoclopramide stimulates aldosterone secretion, we tested its usefulness in the assessment of lateralization of primary aldosteronism by adrenal vein sampling (AVS)." | 7.83 | Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. ( Barbiero, G; Battistel, M; Bisogni, V; Maiolino, G; Miotto, D; Rossi, GP; Rossitto, G; Sanga, V, 2016) |
| "Approximately half of Caucasian patients with essential hypertension and with hyperaldosteronism exhibit elevated circulating levels of endogenous ouabain." | 7.69 | Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. ( De Toni, R; Hamlyn, JM; Manunta, P; Pavan, E; Pessina, AC; Rossi, G; Semplicini, A, 1995) |
| "To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of aldosterone and prolactin stimulation by the dopamine antagonist metoclopramide were established in a pilot study by injecting metoclopramide 1, 2." | 7.67 | Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism. ( Althoff, PH; Jungmann, E; Rosak, C; Schöffling, K; Schwedes, U, 1986) |
| "Plasma aldosterone, 18-hydroxycorticosterone (18-OH-B), 18-hydroxydeoxycorticosterone (18-OH-DOC), corticosterone, cortisol and prolactin levels were determined during an angiotensin II infusion at increasing rates both with and without a simultaneous infusion of dopamine in seven normotensive subjects, in ten patients with essential hypertension, and in ten patients with primary aldosteronism." | 7.67 | Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism. ( Lorenz, R; von Werder, K; Weber, PC; Witzgall, H, 1985) |
| "To investigate possible dopaminergic effects on aldosterone production, we administered the dopamine antagonist metoclopramide to 11 normal subjects, 8 patients with primary aldosteronism due to adenoma or hyperplasia, and 5 other patients with the glucocorticoid-suppressible form of hyperaldosteronism (GSH)." | 7.66 | Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism. ( Fineberg, NS; Ganguly, A; Grim, CE; Pratt, JH; Weinberger, MH, 1983) |
| "To assess the interaction between dopamine and aldosterone secretion in primary aldosteronism, the dopamine antagonist, metoclopramide (methoxy-2-chloro-5-procainamide), was given as an i." | 7.66 | Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism. ( Fukuchi, S; Hashimoto, S; Ikeda, K; Mizuno, K; Yaginuma, K; Yamazaki, M, 1983) |
| "Plasma mineralocorticoid and prolactin levels were evaluated before and 15, 30, 60 and 120 min after the administration of 10 mg metoclopramide in seven normotensive volunteers (42 +/- 5 (SD) years), as well as in ten patients with primary aldosteronism five with aldosterone-producing adenoma (49 +/- 4), and five with bilateral hyperplasia (47 +/- 3)." | 7.66 | Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism. ( von Werder, K; Weber, PC; Witzgall, H, 1983) |
| "The behaviour of plasma renin, aldosterone, cortisol and prolactin after administration of a drug with antidopaminergic action, metoclopramide, was evaluated in 6 normal subjects, 8 patients affected by primary aldosteronism and in 5 patients affected by anterior hypopituitarism." | 7.66 | Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism. ( Armanini, D; Boscaro, M; Fallo, F; Mantero, F; Opocher, G; Valpione, E, 1981) |
| "Cosyntropin and metoclopramide can affect the subtyping of primary aldosteronism when used with adrenal vein sampling by exerting hormone- and side-specific effects on cortisol and aldosterone secretion." | 3.88 | Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide. ( Bisogni, V; Cesari, M; Iacobone, M; Lenzini, L; Maiolino, G; Rossi, GP; Rossitto, G; Seccia, TM, 2018) |
| "As metoclopramide stimulates aldosterone secretion, we tested its usefulness in the assessment of lateralization of primary aldosteronism by adrenal vein sampling (AVS)." | 3.83 | Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. ( Barbiero, G; Battistel, M; Bisogni, V; Maiolino, G; Miotto, D; Rossi, GP; Rossitto, G; Sanga, V, 2016) |
| "To investigate the possible role of dopamine, a catecholamine with natriuretic properties, in modulating the escape from the sodium-retaining effects of mineralocorticoids, we submitted six aldosterone-producing adenoma (APA) patients and six low-renin essential hypertensive patients to acute volume expansion by head-out water immersion with or without dopaminergic blockade by metoclopramide." | 3.69 | Escape from the sodium-retaining effects of mineralocorticoids: is there a role for dopamine? ( Coruzzi, P, 1994) |
| "Approximately half of Caucasian patients with essential hypertension and with hyperaldosteronism exhibit elevated circulating levels of endogenous ouabain." | 3.69 | Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. ( De Toni, R; Hamlyn, JM; Manunta, P; Pavan, E; Pessina, AC; Rossi, G; Semplicini, A, 1995) |
| "Hyperresponsiveness of plasma aldosterone to metoclopramide (MCP) was found in the patients with secondary aldosteronism." | 3.67 | [Influence of endogenous renin-angiotensin system on plasma aldosterone responsiveness to metoclopramide]. ( Iwasaki, Y, 1987) |
| "To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of aldosterone and prolactin stimulation by the dopamine antagonist metoclopramide were established in a pilot study by injecting metoclopramide 1, 2." | 3.67 | Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism. ( Althoff, PH; Jungmann, E; Rosak, C; Schöffling, K; Schwedes, U, 1986) |
| "Plasma aldosterone, 18-hydroxycorticosterone (18-OH-B), 18-hydroxydeoxycorticosterone (18-OH-DOC), corticosterone, cortisol and prolactin levels were determined during an angiotensin II infusion at increasing rates both with and without a simultaneous infusion of dopamine in seven normotensive subjects, in ten patients with essential hypertension, and in ten patients with primary aldosteronism." | 3.67 | Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism. ( Lorenz, R; von Werder, K; Weber, PC; Witzgall, H, 1985) |
| "To assess the interaction between dopamine and aldosterone secretion in primary aldosteronism, the dopamine antagonist, metoclopramide (methoxy-2-chloro-5-procainamide), was given as an i." | 3.66 | Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism. ( Fukuchi, S; Hashimoto, S; Ikeda, K; Mizuno, K; Yaginuma, K; Yamazaki, M, 1983) |
| "Plasma mineralocorticoid and prolactin levels were evaluated before and 15, 30, 60 and 120 min after the administration of 10 mg metoclopramide in seven normotensive volunteers (42 +/- 5 (SD) years), as well as in ten patients with primary aldosteronism five with aldosterone-producing adenoma (49 +/- 4), and five with bilateral hyperplasia (47 +/- 3)." | 3.66 | Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism. ( von Werder, K; Weber, PC; Witzgall, H, 1983) |
| "The behaviour of plasma renin, aldosterone, cortisol and prolactin after administration of a drug with antidopaminergic action, metoclopramide, was evaluated in 6 normal subjects, 8 patients affected by primary aldosteronism and in 5 patients affected by anterior hypopituitarism." | 3.66 | Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism. ( Armanini, D; Boscaro, M; Fallo, F; Mantero, F; Opocher, G; Valpione, E, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (64.29) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 3 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rossitto, G | 2 |
| Maiolino, G | 2 |
| Lenzini, L | 1 |
| Bisogni, V | 2 |
| Seccia, TM | 2 |
| Cesari, M | 1 |
| Iacobone, M | 1 |
| Rossi, GP | 3 |
| Miotto, D | 2 |
| Battistel, M | 1 |
| Barbiero, G | 1 |
| Sanga, V | 1 |
| De Toni, R | 2 |
| Gallina, V | 1 |
| Vincenzi, M | 1 |
| Pessina, AC | 2 |
| Wu, KD | 2 |
| Chen, YM | 2 |
| Chu, TS | 2 |
| Chueh, SC | 1 |
| Tsai, GC | 1 |
| Tseng, YZ | 1 |
| Hsieh, BS | 2 |
| Mizuno, K | 2 |
| Yaginuma, K | 2 |
| Yamazaki, M | 2 |
| Fukuchi, S | 2 |
| Ganguly, A | 1 |
| Pratt, JH | 1 |
| Weinberger, MH | 2 |
| Grim, CE | 1 |
| Fineberg, NS | 1 |
| Ikeda, K | 1 |
| Hashimoto, S | 1 |
| Shimizu, Y | 2 |
| Hanew, K | 1 |
| Sato, S | 1 |
| Sasaki, A | 1 |
| Murakami, O | 1 |
| Yoshinaga, K | 1 |
| Witzgall, H | 3 |
| von Werder, K | 2 |
| Weber, PC | 3 |
| Müller, OA | 1 |
| Mazzacca, G | 1 |
| D'Arienzo, A | 1 |
| Ambrogio, G | 1 |
| Słowińska-Srzednicka, J | 1 |
| Zgliczyński, S | 1 |
| Mantero, F | 1 |
| Opocher, G | 1 |
| Boscaro, M | 1 |
| Valpione, E | 1 |
| Armanini, D | 1 |
| Fallo, F | 1 |
| Gniadek, TC | 1 |
| Grekin, RJ | 1 |
| Gross, MD | 1 |
| Villareal, JZ | 1 |
| Fanning, S | 1 |
| Ishisaka, DY | 1 |
| Merritt, TA | 1 |
| Coruzzi, P | 1 |
| Mune, T | 1 |
| Morita, H | 1 |
| Yasuda, K | 1 |
| Yamakita, N | 1 |
| Miura, K | 1 |
| Naruse, M | 1 |
| Naruse, K | 1 |
| Yoshimoto, T | 1 |
| Tanaka, M | 1 |
| Tanabe, A | 1 |
| Imaki, T | 1 |
| Shibasaki, T | 1 |
| Demura, R | 1 |
| Demura, H | 1 |
| Rossi, G | 1 |
| Manunta, P | 1 |
| Hamlyn, JM | 1 |
| Pavan, E | 1 |
| Semplicini, A | 1 |
| Liao, TS | 1 |
| Lai, MK | 1 |
| Chen, SJ | 1 |
| Su, CT | 1 |
| Chang, CC | 1 |
| Brown, RD | 1 |
| Wisgerhof, M | 1 |
| Carpenter, PC | 1 |
| Brown, G | 1 |
| Jiang, NS | 1 |
| Kao, P | 1 |
| Hegstad, R | 1 |
| Carey, RM | 1 |
| Sen, S | 1 |
| Iwasaki, Y | 1 |
| Jungmann, E | 1 |
| Althoff, PH | 1 |
| Rosak, C | 1 |
| Schwedes, U | 1 |
| Schöffling, K | 1 |
| Lorenz, R | 1 |
| Yanase, T | 1 |
| Nawata, H | 1 |
| Higuchi, K | 1 |
| Kato, K | 1 |
| Ibayashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale andDesign of A Randomized Study (I-PADUA)[NCT03449797] | 200 participants (Anticipated) | Interventional | 2018-04-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metoclopramide and Aldosteronism
| Article | Year |
|---|---|
Recent progress in the control of aldosterone secretion.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Animals; Blood Pressure; Blood Proteins; D | 1986 |
2 trials available for metoclopramide and Aldosteronism
| Article | Year |
|---|---|
[Hyperaldosteronism after metoclopramide administration].
Topics: Adult; Aldosterone; Clinical Trials as Topic; Female; Humans; Hyperaldosteronism; Male; Metocloprami | 1980 |
Dopaminergic regulation of aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aged; Aldosterone; Dopamine; Dopamine Antagonists; Female; | 1995 |
25 other studies available for metoclopramide and Aldosteronism
| Article | Year |
|---|---|
Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide.
Topics: Adrenal Glands; Adult; Aged; Biomarkers; Cosyntropin; Dopamine D2 Receptor Antagonists; Female; Horm | 2018 |
Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism.
Topics: Aldosterone; Female; Humans; Hyperaldosteronism; Male; Metoclopramide; Middle Aged; Prospective Stud | 2016 |
Subtyping of primary aldosteronism by adrenal vein sampling: effect of acute D(2) receptor dopaminergic blockade on adrenal vein cortisol and chromogranin A levels.
Topics: Adrenal Glands; Adult; Aldosterone; Chromogranin A; Dopamine D2 Receptor Antagonists; Female; Humans | 2011 |
Dopaminergic modulation of aldosterone secretions on changes of sodium intake in aldosterone-producing adenoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Diet, Sodium-R | 2002 |
[The effect of metoclopramide, a dopamine inhibitor, on aldosterone secretion in patients with primary aldosteronism].
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Dexamethasone; Dopamine; Female; Humans; Hydrocorti | 1982 |
Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
Topics: Adrenocorticotropic Hormone; Aldosterone; Dexamethasone; Glucocorticoids; Humans; Hydrocortisone; Hy | 1983 |
Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Dexamethasone; Female; Humans; Hydrocortisone; Hype | 1983 |
Primary aldosteronism: diagnosis and differentiation of subtypes.
Topics: Captopril; Diagnosis, Differential; Humans; Hyperaldosteronism; Metoclopramide; Renin-Angiotensin Sy | 1984 |
Evidence for endogenous dopaminergic control of mineralocorticoids secretion in normal subjects and in patients with hyperaldosteronism.
Topics: 18-Hydroxycorticosterone; 18-Hydroxydesoxycorticosterone; Adult; Aldosterone; Desoxycorticosterone; | 1984 |
Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
Topics: Adenoma; Adult; Female; Humans; Hyperaldosteronism; Kinetics; Male; Metoclopramide; Middle Aged; Min | 1983 |
[The role of endogenous dopamine on mineralocorticoids secretion in normal subjects, patients with primary aldosteronism, and idiopathic hyperaldosteronism].
Topics: 18-Hydroxycorticosterone; 18-Hydroxydesoxycorticosterone; Adolescent; Adult; Aldosterone; Desoxycort | 1984 |
Clinical and biochemical features of patients with aldosterone-producing adenoma and idiopathic hyperaldosteronism.
Topics: 18-Hydroxycorticosterone; 18-Hydroxydesoxycorticosterone; Adenoma; Adrenal Cortex Neoplasms; Adult; | 1983 |
Metoclopramide and secondary hyperaldosteronism.
Topics: Humans; Hyperaldosteronism; Metoclopramide | 1983 |
Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism.
Topics: Aldosterone; Humans; Hydrocortisone; Hyperaldosteronism; Hypopituitarism; Metoclopramide; Prolactin; | 1981 |
Hyper-responsiveness of aldosterone to metoclopramide in aldosteronism.
Topics: Aldosterone; Female; Humans; Hydrocortisone; Hyperaldosteronism; Male; Metoclopramide; Potassium; Pr | 1982 |
Possible metoclopramide-induced increase in serum aldosterone in a premature infant.
Topics: Aldosterone; Gastroesophageal Reflux; Humans; Hyperaldosteronism; Infant; Infant, Newborn; Infant, P | 1995 |
Escape from the sodium-retaining effects of mineralocorticoids: is there a role for dopamine?
Topics: Adenoma; Adult; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Creatinine; Dopamine; Female | 1994 |
Reduced response to metoclopramide and anomalous rising response to upright posture of plasma aldosterone concentration in Japanese patients with aldosterone-producing adenoma.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Adult; Aldosterone; Chromatography | 1993 |
Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels.
Topics: Aldosterone; Blood Pressure; Dihydroergotoxine; Dopamine Agonists; Dopamine Antagonists; Female; Hum | 1995 |
Preoperative diagnosis and localization of aldosterone-producing adenoma by adrenal venous sampling after administration of metoclopramide.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Aldoster | 2001 |
Adrenal sensitivity to angiotensin II and undiscovered aldosterone stimulating factors in hypertension.
Topics: Adrenal Glands; Adult; Aldosterone; Dexamethasone; Female; Humans; Hyperaldosteronism; Hypertension; | 1979 |
[Influence of endogenous renin-angiotensin system on plasma aldosterone responsiveness to metoclopramide].
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Diuretics; Dopamine; Female; Humans; Hyperaldostero | 1987 |
Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
Topics: Adult; Aldosterone; Dopamine; Female; Humans; Hyperaldosteronism; Male; Metoclopramide; Middle Aged; | 1986 |
Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism.
Topics: 18-Hydroxycorticosterone; Adult; Aldosterone; Angiotensin II; Blood Pressure; Corticosterone; Depres | 1985 |
[The effects of metoclopramide and dopamine on aldosterone secretion in cultured adrenocortical adenoma cells and adjacent non-adenoma cells from patients with primary aldosteronism].
Topics: Adenoma; Adrenal Cortex; Adrenal Cortex Neoplasms; Adult; Aldosterone; Cells, Cultured; Chromatograp | 1985 |